Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC.
Bolin WangBing ZouShengnan XuChao ZhaoJinli PeiShijie WangKunlong ZhaoJinming YuJie Liu
Published in: Frontiers in oncology (2023)
Postoperative ctDNA detection can be a prognostic marker to predict recurrence but has limited effects in guiding ADT for resectable stage I NSCLC. Future prospective investigations are needed to verify these results.